Dianthus Therapeutics, Inc. (DNTH) Stock Forecast
DNTH analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.94 / 5 from 17 analysts
- Price target
- $140.80 average of analyst targets
- Upside to target
- +95.3% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-1.01
- 52-week range
- $32.92 – $115.96
DNTH analyst ratings
17 analystsNumber of analysts at each rating.
DNTH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DNTH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.95 | −$1.13 | −$0.39 | −$0.97 | +2.2% | 10 |
| Current fiscal year (2026) | −$3.81 | −$4.10 | −$3.43 | −$4.20 | +9.2% | 11 |
| Next fiscal year (2027) | −$4.61 | −$5.77 | −$3.47 | −$3.81 | −20.9% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DNTH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $366,420 | $0 | $1.0M | −7.5% | 14 |
| Current fiscal year (2026) | $1.9M | $900,000 | $3.2M | −8.2% | 14 |
| Next fiscal year (2027) | $1.8M | $0 | $6.0M | −5.1% | 14 |
DNTH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DNTH revenue: reported and forecast
DNTH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.02 | −$1.02 | −$1.02 | −$0.95 | −$0.95 | −7.2% | 2 up · 1 down |
| Current fiscal year (2026) | −$3.93 | −$3.93 | −$3.92 | −$3.81 | −$3.81 | −2.9% | 2 up · 1 down |
| Next fiscal year (2027) | −$4.65 | −$4.65 | −$4.74 | −$4.61 | −$4.61 | −0.9% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DNTH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DNTH beat in 4 of 12.
What analysts expect from DNTH
17 analysts cover Dianthus Therapeutics; their consensus rating is strong buy (4.94 on a 1–5 scale, where 5 is a strong buy). The average price target is $140.80, 95.3% above the latest close of $72.09. Analysts expect earnings of −$3.81 per share for 2026, +9.2% from a year earlier. For 2027 the average estimate is −$4.61 per share on revenue of $1.8 million. Dianthus Therapeutics beat the EPS estimate in 4 of the last 12 quarters.
Related: DNTH income statement, DNTH key metrics, DNTH chart. See the DNTH stock overview for the latest quote and news.
DNTH forecast FAQ
What is Dianthus Therapeutics's price target?
The average analyst price target for Dianthus Therapeutics is $140.80, 95.3% above the latest close of $72.09.
Is Dianthus Therapeutics a buy, hold or sell?
Of 17 analysts covering Dianthus Therapeutics, 16 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Dianthus Therapeutics's EPS forecast?
Analysts forecast −$3.81 per share for 2026 (range −$4.10 to −$3.43); for 2027 the estimate is −$4.61.
What is Dianthus Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $1.9 million, growth of −8.2%; for 2027 it is $1.8 million.
When does Dianthus Therapeutics report earnings?
Dianthus Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-1.01.
Does Dianthus Therapeutics usually beat earnings estimates?
Dianthus Therapeutics reported EPS at or above the analyst estimate in 4 of the last 12 quarters.